Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.58 |
| ▸ | MEN1 | O00255 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3398770 | 1.00 | KMT2A (0.58) | KMT2AMEN1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL7310816 | 0.92 | MEN1 (0.63) | KMT2AMEN1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL16942397 | 0.89 | MEN1 (0.60) | KMT2AMEN1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL3403487 | 0.84 | MAPT (0.48) | KMT2AMEN1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL3405926 | 0.84 | SMN1; SMN2 (0.47) | KMT2AMEN1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL3405931 | 0.84 | SMN1; SMN2 (0.47) | KMT2AMEN1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL22257020 | 0.84 | KMT2A (0.48) | KMT2AMEN1ALDH1A1MAPTHPGD | |
| SCHEMBL3403489 | 0.84 | MAPT (0.48) | KMT2AMEN1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL2950703 | 0.83 | ALDH1A1 (0.54) | KMT2AMEN1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL13243841 | 0.83 | ALDH1A1 (0.54) | KMT2AMEN1ALDH1A1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9387200-B2 | Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity | FIBROGEN, INC. (US) | 2016-07-12 | — | — | US | disclosed |
| US-20150209336-A1 | ISOTHIAZOLE-PYRIDINE DERIVATIVES AS MODULATORS OF HIF (HYPOXIA INDUCIBLE FACTOR) ACTIVITY | FIBROGEN, INC. | 2015-07-30 | — | — | US | disclosed |
| US-8952160-B2 | Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity | FIBROGEN, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-8952160-B2 | Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity | FIBROGEN, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| EP-2252619-B1 | ISOTHIAZOLE-PYRIDINE DERIVATIVES AS MODULATORS OF HIF (HYPOXIA INDUCIBLE FACTOR) ACTIVITY | FIBROGEN INC (US) | 2013-10-09 | — | — | EP | disclosed |
| EP-2252619-B1 | ISOTHIAZOLE-PYRIDINE DERIVATIVES AS MODULATORS OF HIF (HYPOXIA INDUCIBLE FACTOR) ACTIVITY | FIBROGEN INC (US) | 2013-10-09 | — | — | EP | disclosed |
| US-20100330199-A1 | ISOTHIAZOLE-PYRIDINE DERIVATES AS MODULATORS OF HIF (HYPOXIA INDUCIBLE FACTOR) ACTIVITY | FIBROGEN, INC. | 2010-12-30 | — | — | US | disclosed |
| US-20100330199-A1 | ISOTHIAZOLE-PYRIDINE DERIVATES AS MODULATORS OF HIF (HYPOXIA INDUCIBLE FACTOR) ACTIVITY | FIBROGEN, INC. | 2010-12-30 | — | — | US | disclosed |
| EP-2252619-A1 | ISOTHIAZOLE-PYRIDINE DERIVATIVES AS MODULATORS OF HIF (HYPOXIA INDUCIBLE FACTOR) ACTIVITY | Fibrogen, Inc. (US) | 2010-11-24 | — | — | EP | disclosed |
| WO-2009089547-A1 | ISOTHIAZOLE-PYRIDINE DERIVATIVES AS MODULATORS OF HIF (HYPOXIA INDUCIBLE FACTOR) ACTIVITY | FIBROGEN, INC. (US) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100330199-A1 | ISOTHIAZOLE-PYRIDINE DERIVATES AS MODULATORS OF HIF (HYPOXIA INDUCIBLE FACTOR) ACTIVITY | HIF1A, HIF1AN, EGLN3 | KMT2A 967/4885MEN1 4648/4885ALDH1A1 256/4885 |
| US-20150209336-A1 | ISOTHIAZOLE-PYRIDINE DERIVATIVES AS MODULATORS OF HIF (HYPOXIA INDUCIBLE FACTOR) ACTIVITY | HIF1A, HIF1AN, EGLN3 | KMT2A 845/4885MEN1 4694/4885ALDH1A1 284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.